PDCD1 and non-small cell lung carcinoma: Hence, in this study we comprehensively analyzed the TCR-β repertoire in PBMC obtained at two different time points (PRE and FR) from a cohort of 33 advanced NSCLC patients treated in first-line with pembrolizumab, an anti-PD-1 blocker, in monotherapy or in combination with chemotherapy.